Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So, there it is. Nowt new from Futura.
Or did the RNS alone tell the whole story?
Fast forward to the investor call.
Lots of disappointing “no news”: News on product extensions promised last September did not materialise. China, which accounts for c 1/5th of global population, was another area without news. Futura declares that its strategy has shifted to focus on sexual health, begging the question - no answer provided - what will happen to its cannabidiol assets. Will they be sold?
Gold prospecting among all this and more of disappointing material, for me the golden nugget was the clarity of realising that the Big Bang moment in Futura’s share price will be Haleon announcing the launch of sales in the US. The FD stated more than once that when Haleon launches sales in the US, Futura will become profitable. At a stroke, red ink will become black ink. The US launch “expected by early 2025” point in the RNS was explained by the FD as simply a “read across” from Haleon’s February announcement that it planned to launch Eroxon “within the next year”. “Early 2025” is simply a worst case scenario; the best case is well before then.
Nothing else really matters now. Country launches by Cooper and other distributors will be important, but sparklers rather than the explosive firework provided by Haleon launching sales in the US.
At that point, the “keep delivering” mantra of James et al as a response to poor share price performance will, the company expects, turn red ink to black, and thereby create real fruit for long term shareholders.
We just need to remember James’s parting words - “bear with us”.
"The markets are abysmal, too many characters with nanosecond attention spans who need instant gratification"
See it as an opportunity to relieve them of their shares, at a low price.
To me it beggars belief that Futura is saying 'we have one of the largest consumer health companies in the world launching our (FDA approved) product in the U.S. in the next 12 months' and AIM lemmings can only say 'but I want it NOW!!'
Will buy more when all the sheep have left the pen.
No bad news….. profit maybe sooner than first thought….20% market share….. all looks good to me
57% Gross margin on $350m. Tasty.
Let's be conservative for tomas... 30% Gross Margin on $350M, still a Tasty $100M
And that's just the US market.
Before the presentation I posted that PIs are selling for the IIs to accumulate cause these are fantastic results. As James said he’s getting more interest from IIs and considering we are at commercial state of the product being rolled around expect IIs to pile in big time in the next few days and weeks. Those selling today will regret it big time hy next week. Those putting a negative spin on it are traders not investors….and loosers cause trading is loss making as “no one can time the market” per the old city adage, but some idiots keep banging their heads against the stock market wall til their pants drop to show they use their bum not their brain lol.
So in one breath we are told they will not be making running commentary on regulatory approvals or country launches.
In another, Barder says they've got to tell us information as soon as it happens.
But apparently the product has finally had full launch in France, Germany, and I think Spain, and there have been no RNS releases about these. So I guess the first comment about no comms is correct and Barder's comment about his legal duty to inform the market was just gas lighting.
To be clear, he does have a legal duty to inform the market, its just his stated recognition of this that is the gaslighting.
Still, they're embarking on a many-months project to update the website so, like, comms strategy is a go.
That was incredibly frustating as they couldn't or wouldn't answer any questions regarding sales/finance/guidance or anything that would help the sharepirce.
I am a lth and will carry on holding until they release the first half reivew, which should give us a better idea of sales
Hello dear
Reviews of the product seems quite bad, on that alone I wouldn't invest again (was in and out). To be honest, the product does work for me but it seems it's maybe only effective some of the users. I'm concerned about the reviews. I believe that it might build a loyal user base of people like me, who try and stick to it after seeing it works for them but with that presentation card of mostly negative reviews, I would have never bought it in the first place. Sales can grow, little by little but not as quickly as if reviews were stellar
What do you think fellow investor?
Stated to an answer in line with expectations for 2024...dyor etc
He is a safe cautious investor not a major risk taker happy to tke his time its a steady slow safe style take it or leave it
I am involved in another IP rich, commercially sensitive, partner roll out model type business.
That team has no issue providing 3 year forecasts, detail and less of the ''we can't possibly go into that.''
There seems to be a distinct aroma of mutton around today.
Just heard that from CEO
Now we are talking
Because only institutions realy make sp move
The share price you muppet Barder is crucial. It is your job to execute to move the share price.
He is way too blase.
Very disappointed that it seems there's no plan to launch Eroxon in the US this year. I'm also concerned that the EU patent protection for Eroxon may not be robust for all markets.
I'm out, for now anyway..
Okay got the 350m question wrong - that is what the sales will be and not what fum will make...maybe I need to wake up...lol
and of course they cannot answer the question on how much they will make
Why have they not give an indication of revenue /sales forecast for 2024? We are now pretty much in all key EU markets as well as Saudi ( zero feedback on that one considering it is one of the most lucrative markets) and yet no forecast pathetic IMO! Get rid of that CFO who’s it is to forecast these things useless!
WOW... 13% down this morning Barder needs to wake up , stop looking out of the window and show some enthusiasm.
Currently listening to the presentation and find it a waste of time, as every question they say they cannot answer....
also find Barder really doesn't seem to want to be there, more intrested in lookin out the window....
although they say they should make about 350m from the US, according to an IPSOS review (think I got that right)
" on the path towards profitability in the next 12 months."
Careful choice of words.
Could mean anything.
Rpg7
"too many characters with nanosecond attention spans who need instant gratification ."
Im sure that could mean anyone but for myself, I have traded since 2001. I am more than experinced with how markets over react or sell on the news, or no news in this case. I have only been in this 3 years but I class it more than a nano second. Excuse any blunt tones. I am sure we will have our day in the sun but I must say was hardly worth waking up for early this morning.
I am also disappointed, but if the management are so weak (no opinion) then this will become a takeover target with a good premium. I am going to buy more.....
The markets are abysmal, too many characters with nanosecond attention spans who need instant gratification .
"Why put a negative spin on it?"
I think I have been balanced. If you read all my posts this morning. I am not going out of my way to see anything negative. Unlike the markets.
I found the RNS to be underwhelming. The only thing tangible is the 3.1m revenue and 20% of market share. The later was fed to us in the last RNS. The rest is just talking up what we already know.
I do like the talk on ensuring to build up supply lines. But surely this is more of tasking for Coopers/Haleon etc.
I remain largly optimistic in the medium term and no intention of selling.